Clinical Trials Logo

Clinical Trial Summary

FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03372200
Study type Interventional
Source Mochida Pharmaceutical Company, Ltd.
Contact
Status Completed
Phase Phase 3
Start date January 9, 2018
Completion date July 5, 2018

See also
  Status Clinical Trial Phase
Completed NCT03375632 - Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types) Phase 1
Completed NCT03006445 - Study of FYU-981 in Hyperuricemia With or Without Gout Phase 3
Completed NCT03100318 - Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout Phase 3